Clinical lung xenotransplantation - What donor genetic modifications may be necessary?

Xenotransplantation

Volumn 19, Issue 3, 2012, Pages 144-158

  Cooper, David K C ^a   Ekser, Burcin ^a   Burlak, Christopher ^b   Ezzelarab, Mohamed ^a   Hara, Hidetaka ^a   Paris, Leela ^b   Tector, A Joseph ^b   Phelps, Carol ^c   Azimzadeh, Agnes M ^d   Ayares, David ^c   Robson, Simon C ^e   Pierson III, Richard N ^d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c REVIVICOR INC   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

Immune modulation; Immune response; Inflammation; Pig, genetically engineered; Thromboregulation; Xenotransplantation, lung

Indexed keywords

5' NUCLEOTIDASE; ANTIBODY; C REACTIVE PROTEIN; CD39 ANTIGEN; COMPLEMENT; ENDOTHELIAL PROTEIN C RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADAPTIVE IMMUNITY; ALLOTRANSPLANTATION; B LYMPHOCYTE; BLOOD CLOTTING DISORDER; DNA MODIFICATION; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; INFLAMMATORY CELL; INNATE IMMUNITY; LUNG BLOOD VESSEL; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; REVIEW; SURGICAL ANATOMY; SURVIVAL TIME; SWINE; T LYMPHOCYTE; THROMBOSIS; THROMBOSIS PREVENTION; XENOTRANSPLANTATION;

ANIMALS; GENETIC ENGINEERING; HUMANS; IMMUNOMODULATION; LUNG TRANSPLANTATION; SWINE; TISSUE DONORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84862528464     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2012.00708.x     Document Type: Review

References (208)

1. BRYANT LR, EISEMAN B, AVERY M. Studies of the porcine lung as an oxygenator for human blood. J Thorac Cardiovasc Surg 1968; 55: 255-263.
2. KAPLON RJ, PLATT JL, KWIATKOWSKI PA et al. Absence of hyperacute rejection in pig-to-primate orthotopic pulmonary xenografts. Transplantation 1995; 59: 410-416.
3. KAMHOLZ SL, BREWER RJ, GRIJALVA G et al. Laboratory studies in cross-species lung transplantation. World J Surg 1997; 21: 951-955.
4. MACCHIARINI P, MAZMANIAN GM, ORIOL R et al. Ex vivo lung model of pig-to-human hyperacute xenograft rejection. J Thorac Cardiovasc Surg 1997; 114: 315-325.
5. MACCHIARINI P, ORIOL R, AZIMZADEH A et al. Evidence of human non-alpha-galactosyl antibodies involved in the hyperacute rejection of pig lungs and their removal by pig organ perfusion. J Thorac Cardiovasc Surg 1998; 116: 831-843.
6. DAGGETT CW, YEATMAN M, LODGE AJ et al. Swine lungs expressing human complement-regulatory proteins are protected against acute pulmonary dysfunction in a human plasma perfusion model. J Thorac Cardiovasc Surg 1997; 113: 390-398.
7. DAGGETT CW, YEATMAN M, LODGE AJ et al. Total respiratory support from swine lungs in primate recipients. J Thorac Cardiovasc Surg 1998; 115: 19-27.
8. BLUM MG, COLLINS BJ, CHANG AC, ZHANG JP, KNAUSSA, PIERSON RN 3RD. Complement inhibition by FUT- 175 and K76-COOH in a pig-to-human lung xenotransplant model. Xenotransplantation 1998; 5: 35-43.
9. LAU CL, DAGGETT WC, YEATMAN MF et al. The role of antibodies in dysfunction of pig-to-baboon pulmonary transplants. J Thorac Cardiovasc Surg 2000; 120: 29-38.
10. LAU CL, CANTU E 3RD, GONZALEZ-STAWINSKI GV et al. The role of antibodies and von Willebrand factor in discordant pulmonary xenotransplantation. Am J Transplant 2003; 3: 1065-1075.
11. WIEBE K, STEINHOFF G, POELING J et al. Ex vivo perfusion of swine lungs: lung function in a pig-to-human model of xenotransplantation. Transplant Proc 2000; 32: 1149-1150.
12. GACA JG, LEE W, AKSOY O et al. Evidence of polyreactive xenoreactive antibodies in the repertoire of human anti-swine lung antibodies: the 'next' humoral barrier to xenotransplantation? Transplant Immunol 2001; 9: 19-27.
13. GACA JG, LESHER A, AKSOY O et al. Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. Transplantation 2002; 73: 1717-1723.
14. GACA JG, LESHER A, AKSOY O et al. The role of porcine von Willebrand factor-baboon platelet interactions in disseminated intravascular coagulation associated with pulmonary xenotransplantation. Transplantation 2002; 74: 1596-1603.
15. GACA JG, PALESTRANT D, LUKES DJ et al. Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate. J Surg Res 2003; 112: 19-25.
16. GONZALEZ-STAWINSKI GV, DAGGETT CW, LAU CL et al. Non-anti-Galα1- 3Gal antibody mechanisms are sufficient to cause hyperacute lung dysfunction in pulmonary xenotransplantation. J Am Coll Surg 2002; 194: 765-773.
17. CANTU E, PARKER W, PLATT JL, DAVIS RD. Pulmonary xenotransplantation: rapidly progressing into the unknown. Am J Transplant 2004; 4(Suppl. 6): 25-35.
18. CANTU E, GACA JG, PALESTRANT D et al. Depletion of pulmonary intravascular macrophages prevents hyperacute pulmonary xenograft dysfunction. Transplantation 2006; 81: 1157-1164.
19. CANTU E, BALSARA KR, LI B et al. Prolonged function of macrophage, von Willebrand factor-deficient porcine pulmonary xenografts. Am J Transplant 2007; 7: 66-75.
20. NGUYEN BN, AZIMZADEH AM, SCHROEDER C et al. Absence of Gal epitope prolongs survival of swine lungs in an ex vivo model of hyperacute rejection. Xenotransplantation 2011; 18: 94-107 [Erratum in Xenotransplantation 2011;18:267].
21. NGUYEN B-NH, AZIMZADEH AM, ZHANG T et al. Life-supporting function of genetically modified swine lungs in baboons. J Thorac Cardiovasc Surg 2007; 133: 1354-1363 [Erratum J Thorac Cardiovasc Surg. 2008;135:28A].
22. STODDARD TA, KELISHADI SS, ZHANG T et al. Administration of clodronate confers added protection against HALR. J Surg Res 2008; 144: 447.
23. KIM YT, LEE HJ, LEE SW et al. Pre-treatment of porcine pulmonary xenograft with desmopressin: a novel strategy to attenuate platelet activation and systemic intravascular coagulation in an ex-vivo model of swine-to-human pulmonary xenotransplantation. Xenotransplantation 2008; 15: 27-35.
24. BUSH EL, BARBAS AS, HOLZKNECHT ZE et al. Coagulopathy in α-galactosyl transferase knockout pulmonary xenotransplants. Xenotransplantation 2011; 18: 6-13.
25. COLLINS BJ, BLUM MG, PARKER RE et al. Thromboxane mediates pulmonary hypertension and lung inflammation during hyperacute lung rejection. J Appl Physiol 2001; 90: 2257-2268.
26. HOLZKNECHT ZE, COOMBES S, BLOCHER BA, LAU CL, DAVIS RD, PLATT JL. Identification of antigens on porcine pulmonary microvascular endothelial cells recognized by human xenoreactive natural antibodies. Lab Invest 1999; 79: 763-773.
27. KNOSALLA C, YAZAWA K, BEHDAD A et al. Renal and cardiac endothelial heterogeneity impact acute vascular rejection in pig-to-baboon xenotransplantation. Am J Transplant 2009; 9: 1006-1016.
28. PLATT J, DISESA V, GAIL D, MASSICOT-FISHER J. Recommendations of the National Heart, Lung, and Blood Institute Heart and Lung Xenotransplantation Working Group. Circulation 2002; 106: 1043-1047.
29. EKSER B, RIGOTTI P, GRIDELLI B, COOPER DKC. Xenotransplantation of solid organs in the pig-to-primate model. Transpl Immunol 2009; 21: 87-92.
30. PIERSON RN 3RD, DORLING A, AYARES D et al. Current status of xenotransplantation and prospects for clinical application. Xenotransplantation 2009; 16: 263-280.
31. PIERSON RN 3RD, DUNNING JJ, KONIG WK et al. Mechanisms governing the pace and character of pig heart-lung rejection by human blood. Transplant Proc 1994; 26: 2337.
32. PIERSON RN 3RD, KASPER-KONIG W, TEW DN et al. Hyperacute lung rejection in a pig-to-human transplant model: the role of anti-pig antibody and complement. Transplantation 1997; 63: 594-603.
33. PIERSON RN III, PINO-CHAVEZ G, YOUNG VK, KASPER- KONIG W, WHITE DJG, WALLWORK J. Expression of human decay accelerating factor may protect pig lung from hyperacute rejection by human blood. J Heart Lung Transplant 1997; 16: 231-239.
34. YEATMAN M, DAGGETT CW, LAU CL et al. Human complement regulatory proteins protect swine lungs from xenogeneic injury. Ann Thorac Surg 1999; 67: 769-775.
35. KUWAKI K, TSENG YL, DOR FJ et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase geneknockout pigs as donors: initial experience. Nat Med 2005; 11: 29-31.
36. MCGREGOR CGA, DAVIES WR, OI K et al. Cardiac xenotransplantation: recent preclinical progress with 3- month median survival. J Thorac Cardiovasc Surg 2005; 130: 844-851.
37. MOHIUDDIN MM, CORCORAN PC, SINGH AK et al. B-cell depletion extends the survival of GTKO.hCD46Tg pig heart xenografts in baboons for up to 8 months. Am J Transplant 2012; 12: 763-771.
38. EKSER B, EZZELARAB M, HARA H et al. Clinical xenotransplantation: the next medical revolution? Lancet 2012; 379: 672-683.
39. VIAL CM, OSTLIE DJ, BHATTI FN et al. Life supporting function for over one month of a transgenic porcine heart in a baboon. J Heart Lung Transplant 2000; 19: 224-229.
40. BRENNER P, SCHMOECKEL M, WIMMER C et al. Mean xenograft survival of 14.6 days in a small group of hDAF-transgenic pig hearts transplanted orthotopically into baboons. Transplant Proc 2005; 37: 472-476.
41. MCGREGOR CGA, BYRNE GW, VLASIN M et al. Early cardiac function and gene expression after orthotopic cardiac xenotransplantation. Xenotransplantation 2009; 16: 356 (Abstract #IXA-O-2.4).
42. COZZI E, VIAL C, OSTLIE D et al. Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts. Xenotransplantation 2003; 10: 300-310.
43. YAMADA K, YAZAWA K, SHIMIZU A et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase geneknockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11: 32-34.
44. RAMIREZ P, CHAVEZ R, MAJADO M et al. Life-supporting human complement regulator decay accelerating factor transgenic pig liver xenograft maintains the metabolic function and coagulation in the nonhuman primate for up to 8 days. Transplantation 2000; 70: 989-998.
45. EKSER B, LONG C, ECHEVERRI GJ et al. Impact of thrombocytopenia on survival of baboons with genetically- modified pig liver transplants: clinical relevance. Am J Transplant 2010; 10: 273-285.
46. SCHUETZ C, KIM K, ELIAS N et al. 9-day survival and control of thrombocytopenia following liver xenotransplantation in baboons using GalT-KO swine grafts. Xenotransplantation 2011; 18: 314 (Abstract #P245).
47. ZHANG JP, BLUM MG, CHANG AC et al. Immunohistologic evaluation of mechanisms mediating hyperacute lung rejection, and the effect of treatment with K76 COOH, FUT 175, and anti Gal column immunoadsorption. Xenotransplantation 1999; 6: 249-261.
48. AZIMZADEH A, ZORN GL III, BLAIR KSA et al. Hyperacute lung rejection in the pig-to-human model. 2. Synergy between soluble and membrane complement inhibition. Xenotransplantation 2003; 10: 120-131.
49. ZORN GL III, PFEIFFER S, AZIMZADEH A, PIERSON RNIII. Thrombin inhibition protects the pulmonary xenograft from hyperacute rejection. Surg Forum 2000; LI: 338-340.
50. PFEIFFER S, ZORN GL III, KELISHADI S et al. Role of anti-Galα1,3Gal and anti-platelet antibodies in hyperacute rejection of pig lung by human blood. Ann Thorac Surg 2001; 72: 1681-1689.
51. HOLZKNECHT ZE, COOMBES S, BLOCHER BA et al. Immune complex formation after xenotransplantation: evidence of type III as well as type II immune reactions provide clues to pathophysiology. Am J Pathol 2001; 158: 627-637.
52. O'BRIEN JR. Shear induced platelet aggregation. Lancet 1990; 335: 711-713.
53. KROLL MH, HARRIS TS, MOAKE JL et al. Von Willebrand factor binding to platelet GPIb initiates signals for platelet activation. J Clin Invest 1991; 88: 1568-1573.
54. GOTO S, SALOMON DR, IKEDA Y et al. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995; 270: 23352-23361.
55. PARETI FI, MAZZUCATO M, BOTTINI E, MANNUCCI PM.Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex. Br J Haematol 1992; 82: 81-86.
56. MAZZUCATO M, DE MARCO L, PRADELLA P, MASOTTI A, PARETI FI. Porcine von Willebrand factor binding to human platelets GPIb induces transmembrane calcium influx. Thromb Haemost 1996; 75: 655-660.
57. SCHMELZLE M, SCHULTE AM ESCH J 2ND, ROBSON SC.Coagulation, platelet activation and thrombosis in xenotransplantation. Curr Opin Organ Transplant 2010; 15: 212-218.
58. EZZELARAB M, GARCIA B, AZIMZADEH A et al. The innate immune response and activation of coagulation in α1,3-galactosyltransferase gene-knockout xenograft recipients. Transplantation 2009; 87: 805-812.
59. SCHROEDER C, SANGRAMPURKAR N, HU J et al. Role of HMGB1 in lung xenograft injury and cytokine production. Xenotransplantation 2009; 16: 431 (Abstract #P-18.6).
60. LIN CC, EZZELARAB M, SHAPIRO R et al. Tissue factor expression on recipient platelets is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation. Am J Transplant 2010;10:1556-1568.
61. COZZI E, WHITE DJG. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964-969.
62. YEATMAN M, DAGGETT CW, PARKER W et al. Complement- mediated pulmonary xenograft injury: studies in swine-to-primate orthotopic single lung transplant models. Transplantation 1998; 65: 1084-1093.
63. KULICK DM, SALERNO CT, DALMASSO AP et al. Transgenic swine lungs expressing human CD59 are protected from injury in a pig-to-human model of xenotransplantation. J Thorac Cardiovasc Surg 2000; 119: 690-699.
64. MIYAGAWA S, YAMAMOTO A, MATSUNAMI K et al. Complement regulation in the GalT KO era. Xenotransplantation 2010; 17: 11-25.
65. AZIMZADEH AM, KELISHADI S, EZZELARAB M et al. Early graft failure of GTKO pig organs in baboons is reduced by HCPRP expression. Am J Transplant 2010; 10(Suppl. 4): 186 (Abstract #499).
66. MORGAN BP, BERG CW, HARRIS CL. "Homologous restriction" in complement lysis: roles of membrane complement regulators. Xenotransplantation 2005; 12: 258-265.
67. HURH S, CHOI I, CHO B et al. Human xenogeneic responses to HD antigen in xenotransplantation. Xenotransplantation 2011; 18: 273 (Abstract #135).
68. VARKI A. Loss of N-glycolylneuraminic acid in humans: mechanisms, consequences, and implications for hominid evolution. Am J Phys Anthropol 2001; (Suppl. 33): 54-69.
69. ZHU A, HURST R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002; 9: 376-381.
70. TANGVORANUNTAKUL P, GAGNEUX P, DIAZ S et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A 2003; 100: 12045-12050.
71. MIWA Y, KOBAYASHI T, NAGASAKA T et al. Are N-glycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation. Xenotransplantation 2004; 11: 247-253.
72. TAHARA H, IDE K, BASNET NB et al. Immunological property of antibodies against N-glycolylneuraminic acid epitopes in cytidine monophospho-N- acetylneuraminic acid hydroxylase-deficient mice. J Immunol 2010; 184: 3269-3275.
73. PADLER-KARAVANI V, VARKI A. Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk. Xenotransplantation 2011; 18: 1-5.
74. COOPER DKC. Xenoantigens and xenoantibodies. Xenotransplantation 1998; 5: 6-17.
75. EZZELARAB M, AYARES D, COOPER DKC. Carbohydrates in xenotransplantation. Immunol Cell Biol 2005; 83: 396-404.
76. BYRNE GW, STALBOERGER PG, DAVILA E et al. Proteomic identification of non-Gal antibody targets after pigto- primate cardiac xenotransplantation. Xenotransplantation 2008; 15: 268-276.
77. BYRNE GW, STALBOERGER PG, DU Z, DAVIS TR, MCGREGOR CG. Identification of new carbohydrate and membrane protein antigens in cardiac xenotransplantation. Transplantation 2011; 91: 287-292.
78. YEH P, EZZELARAB M, BOVIN N et al. Investigation of potential carbohydrate antigen targets for human and baboon antibodies. Xenotransplantation 2010; 17: 197-206.
79. BREIMER ME. Gal/non-Gal antigens in pig tissues and human non-Gal antibodies in the GalT-KO era. Xenotransplantation 2011; 18: 215-228.
80. BURLAK C, WANG ZY, CHIHARA RK et al. Identification of human preformed antibody targets in GTKO pigs. Xenotransplantation 2012; 19: 92-101.
81. D'APICE AJ, COWAN PJ. Xenotransplantation: the next generation of engineered animals. Transpl Immunol 2009; 21: 111-115.
82. INVERARDI L, CLISSI B, STOLZER AL et al. Human natural killer lymphocytes directly recognize evolutionarily conserved oligosaccharide ligands expressed by xenogeneic tissues. Transplantation 1997; 63: 1318-1330.
83. BAUMANN BC, FORTE P, HAWLEY RJ, RIEBEN R, SCHNEIDER MK, SEEBACH JD. Lack of galactose-α1,3- galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. J Immunol 2004; 172: 6460-6467.
84. RIEBEN R, SEEBACH JD. Xenograft rejection: IgG1, complement and NK cells team up to activate and destroy the endothelium. Trends Immunol 2005; 26: 2-5.
85. HORVATH-ARCIDIACONO JA, PORTER CM, BLOOM ET. Human NK cells can lyse porcine endothelial cells independent of their expression of Galalpha(1,3)-Gal and killing is enhanced by activation of either effector or target cells. Xenotransplantation 2006; 13: 318-327.
86. KENNETT SB, PORTER CM, HORVATH-ARCIDIACONO JA, BLOOM ET. Characterization of baboon NK cells and their xenogeneic activity. Xenotransplantation 2010; 17: 288-299.
87. SEEBACH JD, COMRACK C, GERMANA S, LEGUERN C, SACHS DH, DERSIMONIAN H. HLA-Cw3 expression on porcine endothelial cells protects against xenogeneic cytotoxicity mediated by a subset of human NK cells. J Immunol 1997; 159: 3655-3661.
88. DORLING A, MONK NJ, LECHLER RI. HLA-G inhibits the transendothelial migration of human NK cells. Eur J Immunol 2000; 30: 586-593. (Pubitemid 30098852)
89. SHARLAND A, PATEL A, LEE JH et al. Genetically modified HLA class I molecules able to inhibit human NK cells without provoking alloreactive CD8+ CTLs. J Immunol 2002; 168: 3266-3274.
90. FORTE P, BAUMANN BC, WEISS EH, SEEBACH JD. HLAE expression on porcine cells: protection from human NK cytotoxicity depends on peptide loading. Am J Transplant 2005; 5: 2085-2093.
91. CREW MD, CANNON MJ, PHANAVANH B, GARCIA-BORGES CN. An HLA-E single chain trimer inhibits human NK cell reactivity towards porcine cells. Mol Immunol 2005; 42: 1205-1214.
92. CREW MD. Play it in E or G: utilization of HLA-E and -G in xenotransplantation. Xenotransplantation 2007; 14: 198-207.
93. WEISS EH, LILIENFELD BG, MÜLLER S et al. HLA-E/ human beta2-microglobulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity. Transplantation 2009; 87: 35-43.
94. HARA H, CROSSLEY T, WITT W et al. Dominant-negative CIITA transgenic pigs - effect on the human anti-pig T cell immune response and immune status. Am J Transplant 2010; 10(Suppl. 4): 187 (Abstract #503).
95. PHELPS C, BALL S, VAUGHT T et al. Production and characterization of transgenic pigs expressing porcine CTLA4-Ig. Xenotransplantation 2009; 16: 477-485.
96. BRAIN JD, MOLINA RM, DECAMP MM, WARNER AE.Pulmonary intravascular macrophages: their contribution to the mononuclear phagocyte system in 13 species. Am J Physiol 1999; 276: L146-L154.
97. WINKLER GC, CHEVILLE NF. Monocytic origin and postnatal mitosis of intravascular macrophages in the porcine lung. J Leukoc Biol 1985; 38: 471-480.
98. WINKLER GC, CHEVILLE NF. Postnatal colonization of porcine lung capillaries by intravascular macrophages: an ultrastructural, morphometric analysis. Microvasc Res 1987; 33: 224-232.
99. MIYAMOTO K, SCHULTZ E, HEATH T et al. Pulmonary intravascular macrophages and hemodynamic effects of liposomes in sheep. J Appl Physiol 1988; 64: 1143-1152.
100. CHITKO-MCKOWN CG, CHAPES SK, BROWN RE et al. Porcine alveolar and pulmonary intravascular macrophages: comparison of immune functions. J Leukocyte Biol 1991; 50: 364-372.
101. PARIS L, REYES LM, TECTOR AJ et al. SIRPA interspecies incompatibilities lead to xenogeneic phagocytosis of platelets by liver cells. Xenotransplantation 2011; 18: 293 (Abstract #411).
102. IDE K, OHDAN H, KOBAYASHI T, HARA H, ISHIYAMA K, ASAHARA T. Antibody- and complement-independent phagocytotic and cytolytic activities of human macrophages toward porcine cells. Xenotransplantation 2005; 12: 181-188.
103. IDE K, WANG H, TAHARA H et al. Role for CD47- SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad Sci U S A 2007; 14: 5062-5066.
104. YANG YG. CD47 in xenograft rejection and tolerance induction. Xenotransplantation 2010; 17: 267-273.
105. NAVARRO-ALVAREZ N, YANG YG. CD47: a new player in phagocytosis and xenograft rejection. Cell Mol Immunol 2011; 8: 285-288.
106. SUBRAMANIAN S, TSAI R, DISCHER DE. The 'metabolon,'CD47, and the 'phagocytic synapse': molecular co-localization and species divergence. Transfus Clin Biol 2006; 13: 31-38.
107. ROBSON SC, WU Y, SUN X, KNOSALLA C, DWYER K,ENJYOJI K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 2005; 31: 217-233.
108. DEAGLIO S, ROBSON SC. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol 2011; 61: 301-332.
109. TAKENAKA K, PRASOLAVA TK, WANG JC et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 2007; 8: 1313-1323.
110. STAUB NC. Pulmonary intravascular macrophages. Ann Rev Physiol 1994; 56: 47-67.
111. SONE Y, NICOLAYSEN A, STAUB NC. Effect of particles on sheep lung hemodynamics parallels depletion and recovery of intravascular macrophages. J Appl Physiol 1997; 83: 1499-1507.
112. SONE Y, SERIKOV KB, STAUB NC. Intravascular macrophage depletion attenuates endotoxin in lung injury in anesthetized sheep. J Appl Physiol 1999; 87: 1354-1359.
113. BURDORF L, ZHANG T, RYBAK E et al. Anti-GP1b Fab reduces activation and sequestration of platelets in a xenogeneic pig lung perfusion model. Transplantation 2010; 90: 422 (Abstract #223.3).
114. BURDORF L, BARTH R, ZHANG T et al. Pilot evaluation of anti-GP1b effects on platelet sequestration in an ex-vivo xenogeneic pig liver perfusion model. Transplantation 2010; 90: 327 (Abstract #202.3).
115. BURDORF L, ZHANG T, RYBAK E et al. Combined GPIb and GPIIb/IIIa blockade prevents sequestration of platelets in a pig-to-human lung perfusion model. Xenotransplantation 2011; 18: 287 (Abstract #392).
116. TENA A, TURCOTTE N, BARONE AAL et al. Miniature swine expressing human CD47 to enhance bone marrow engraftment in non-human primates. Xenotransplantation 2011; 18: 271 (Abstract #127).
117. KUES WA, SCHWINZER R, WIRTH D et al. Epigenetic silencing and tissue independent expression of a novel tetracycline inducible system in double- transgenic pigs. FASEB J 2006; 20: 1200-1202.
118. LI L, PANG D, WANG T et al. Production of a reporter transgenic pig for monitoring Cre recombinase activity. Biochem Biophys Res Commun 2009; 382: 232-235.
119. ISENBERG JS, ROMEO MJ, ABU-ASAB M et al. Increasing survival of ischemic tissue by targeting CD47. Circ Res 2007; 100: 712-720.
120. ROBERTS DD, MILLER TW, ROGERS NM, YAO M, ISENBERG JS. The matricellular protein thrombospondin- 1 globally regulates cardiovascular function and responses to stress. 2012; 31: 162-169.
121. ISENBERG JS, RIDNOUR LA, DIMITRY J, FRAZIER WA, WINK DA, ROBERTS DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006; 281: 26069-26080.
122. ISENBERG JS, ANNIS DS, PENDRAK ML et al. Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 2009; 284: 1116-1125.
123. LAMY L, TICCHIONI M, ROUQUETTE-JAZDANIAN AK et al. CD47 and the 19 kDa interacting protein-3 (BNIP3) in T cell apoptosis. J Biol Chem 2003; 278: 23915-23921.
124. LAMY L, FOUSSAT A, BROWN EJ, BORNSTEIN P, TICCHIONI M, BERNARD A. Interactions between CD47 and thrombospondin reduce inflammation. J Immunol 2007; 178: 5930-5939.
125. ISENBERG JS, ROMEO MJ, YU C et al. Thrombospondin-1 stimulates platelet aggregation by blocking the anti-thrombotic activity of nitric oxide/cGMP signaling. Blood 2008; 111: 613-623.
126. KLOSE R, KEMTER E, BEDKE T et al. Expression of biologically active human TRAIL in transgenic pigs. Transplantation 2005; 80: 222-230.
127. KEMTER E, LIEKE T, KESSLER B et al. Human TNF-related apoptosis-inducing ligand-expressing dendritic cells from transgenic pigs attenuate human xenogeneic T cell responses. Xenotransplantation 2012; 19: 40-51.
128. BOZEMAN EN, HOOD JD, SHASHIDHARAMURTHY R, SELVARAJ P. 'Exhaustive' look at PD-1/PDL-1 blockade in vivo. Immunotherapy 2009; 1: 525-527.
129. SIEGEL JB, GREY ST, LESNIKOSKO BA et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64: 888-896.
130. SCHULTE AM ESCH J, ROGIERS X, ROBSON SC. Molecular incompatibilities in hemostasis between swine and men - impact on xenografting. Ann Transplant 2001; 6: 12-16.
131. COWAN PJ, ROBSON SC, D'APICE AJF. Controlling coagulation dysregulation in xenotransplantation. Curr Opin Organ Transplant 2011; 16: 214-221.
132. LAWSON JH, DANIELS LJ, PLATT JL. The evaluation of thrombomodulin activity in porcine to human xeno-transplantation. Transplant Proc 1997; 29: 884-885.
133. ESMON CT. The protein C pathway. Chest 2003; 124: 26S-32S.
134. ESMON CT, OWEN WG. The discovery of thrombomodulin. J Thromb Haemost 2004; 2: 209-213.
135. ROUSSEL JC, MORAN CJ, SALVARIS EJ et al. Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transplant 2008; 8: 1101-1112.
136. IWAMOTO M, YAZAKI S, ONISHI A et al. Successful production and breeding of cloned pigs expressing human thrombomodulin in endothelial cells. Xenotransplantation 2011; 18: 270 (Abstract 125).
137. KLYMIUK N, WUENSCH A, KUROME M et al. GalT-KO/ CD46/hTM triple-transgenic donor animals for pig-to-baboon heart transplantation. Xenotransplantation 2011; 18: 271 (Abstract #126).
138. SALVARIS E, FISICARO N, HARRISON S et al. Expression of human thrombomodulin in GTKO/hCD55-CD59- HTF pigs. Xenotransplantation 2011; 18: 296 (Abstract #513).
139. PETERSEN B, RAMACKERS W, TIEDE A et al. Pigs transgenic for human thrombomodulin have elevated production of activated protein C. Xenotransplantation 2009; 16: 486-495.
140. CRIKIS S, ZHANG XM, DEZFOULI S et al. Anti-inflammatory and anticoagulant effects of transgenic expression of human thrombomodulin in mice. Am J Transplant 2010; 10: 242-250.
141. MIWA Y, YAMAMOTO K, ONISHI A et al. Potential value of human thrombomodulin and DAF expression for coagulation control in pig-to-humanxenotransplantation. Xenotransplantation 2010; 17: 26-37.
142. ESMON CT. Structure and functions of the endothelial cell protein C receptor. Crit Care Med 2004; 32: S298-S301.
143. ESMON CT. The endothelial protein C receptor. Curr Opin Hematol 2006; 13: 382-385.
144. ESMON CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32: 49-60.
145. ESMON CT. The discovery of the endothelial cell protein C receptor. J Thromb Haemost 2010; 8: 2-5.
146. LEE KF, SALVARIS EJ, ROUSSEL JC et al. Recombinant pig TFPI efficiently regulates human tissue factor. Xenotransplantation 2008; 15: 191-197.
147. KOPP CW, SIEGEL JB, HANCOCK WW et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63: 749-758.
148. CHEN D, GIANNOPOULOS K, SHIELS PG et al. Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium. Blood 2004; 104: 1344-1349.
149. CHEN D, WEBER M, MCVEY JH et al. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4: 1958-1963.
150. SCHELZIG H, VOGEL A, KRISCHER C, SIMON F, ABENDROTH D. Role of recombinant hirudin in a pig-to-human lung transplantation model. Transplant Proc 2002; 34: 2384-2386.
151. BRUMMELKAMP TR, BERNARDS R, AGAMI R. A system for stable expression of small interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
152. COUZIN J. Breakthrough of the year. Small RNAs make big splash. Science 2002; 298: 2296-2297.
153. DALLAS S, VLASSOV AV. RNAi: a novel antisense technology and its therapeutic potential. Med Sci Monit 2006; 12: RA67-RA74.
154. LE HIR M, KAISSLING B. Distribution and regulation of renal ecto-5′-nucleosidase: implications for physiological functions of adenosine. Am J Physiol 1993; 264: F377-F387.
155. KACZMAREK E, KOZIAK K, SEVIGNY J et al. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 1996; 271: 33116-33122.
156. SMOLENSKI RT, KOCHAN Z, KARBOWSKA J et al. Low expression of ecto-5′- nucleosidase in the pig heart - a potential barrier to xenotransplantation. J Heart Lung Transplant 2001; 20: 214-215.
157. SMOLENSKI RT, KHALPEY Z, YUEN AC et al. Purine metabolism in pigs and humans and implications for xenotransplantation. Nucleosides, Nucleotides Nucleic Acids 2005; 24: 263-266.
158. SMOLENSKI RT, KHALPEY Z, OSBORNE FN et al. Species differences of endothelial extracellular nucleotide metabolism and its implications for xenotransplantation. Pharmacol Rep 2006; 58(Suppl.): 118-125.
159. DEAGLIO S, DWYER KM, GAO W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
160. DWYER KM, ROBSON SC, NANDURKAR HH et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004; 113: 1440-1446.
161. DWYER KM, MYSORE TB, CRIKIS S et al. The transgenic expression of human CD39 on murine islets inhibits clotting of human blood. Transplantation 2006; 82: 428-432.
162. DWYER KM, DEAGLIO S, GAO W et al. CD39 and control of cellular immune responses. Purinergic Signal 2007; 3: 171-180.
163. DI VIRGILIO F, BOEYNAEMS JM, ROBSON SC. Extracellular nucleotides as negative modulators of immunity. Curr Opin Pharmacol 2009; 9: 507-513.
164. CRIKIS S, LU B, MURRAY-SEGAL LM et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant 2010; 10: 2586-2595.
165. LE BAS-BERNARDET S, BRANCHEREAU J, TILLOU X et al. Porcine galactosyl- transferase knock-out transgenic for human CD55, CD59, CD39 kidneys are actually rejected by baboons despite plasma/B cells and complement blockade. Xenotransplantation 2011; 18: 298 (Abstract #556).
166. LE BAS-BERNARDET S, POIRIER N, TILLOU X et al. Preformed non-Gal antibodies are highly cytotoxic even against Galactosyl-transferase knockout, human CD55, CD59, CD39 transgenic pig organs in a model of kidney transplantation into baboons. Xenotransplantation 2011; 18: 298 (Abstract #557).
167. HASKÓG, CSÓKA B, KOSCSÓ B et al. Ecto-5′-nucleotidase (CD73) decreases mortality and organ injury in sepsis. J Immunol 2011; 187: 4256-4267.
168. ESMON CT. Protein C anticoagulant system-anti-inflammatory effects. Semin Immunopathol 2012; 34: 127-132.
169. ESMON CT, XU J, LUPU F. Innate immunity and coagulation. J Thromb Haemost 2011; 9: 182-188.
170. PETERSON B, LUCAS-HARN A, LEMME E et al. Generation and characterization of pigs transgenic for human hemeoxygenase-1 (hHO-1). Xenotransplantation 2010; 17: 102-103.
171. PETERSON B, RAMACKERS W, LUCAS-HAHN A et al. Transgenic expression of human heme oxygenase-1 in pigs confers resistance against xenograft rejection during ex vivo perfusion of porcine kidneys. Xenotransplantation 2011; 18: 355-368.
172. SCHWINZER R, BAARS W, BORNS K, PETERSEN B, KUES W, NIEMANN H. Over-expression of of human HO-1 and A20 in porcine cells: effects on susceptibility to cell-mediated lysis and inflammatory cytokines. Xenotransplantation 2011; 18: 269 (Abstract #122).
173. OROPEZA M, PETERSEN B, CARNWATH JW et al. Transgenic expression of the human A20 gene in cloned pigs provides protection against apoptotic and inflammatory stimuli. Xenotransplantation 2009; 16: 522-534.
174. CHO B, KOO OJ, HWANG JI et al. Generation of soluble human tumor necrosis factor-α receptor 1-Fc transgenic pig. Transplantation 2011; 92: 139-147.
175. CAMPBELL PD, WEINBERG A, CHEE J et al. Expression of pro- and anti-apoptotic molecules of the Bcl-2 family in human islets post-isolation. Cell Transplant 2012; 21: 49-60.
176. EZZELARAB M, AYARES D, COOPER DKC. The potential of genetically-modified pig mesenchymal stromal cells in xenotransplantation. Xenotransplantation 2010; 17: 3-5.
177. EZZELARAB M, EZZELARAB C, WILHITE T et al. Genetically- modified pig mesenchymal stromal cells: xenoantigenicity and effect on human T-cell xenoresponses. Xenotransplantation 2011; 18: 183-195.
178. PORTER CM, HORVATH-ARCIDIACONO JA, SINGH AK, HORVATH KA, BLOOM ET, MOHIUDDIN MM. Characterization and expansion of baboon CD4+CD25+ Treg cells for potential use in a non-human primate xenotransplantation model. Xenotransplantation 2007; 14: 298-308.
179. FU Y, YI S, WU J et al. In vitro suppression of xenoimmune- mediated macrophage activation by human CD4+CD25+ regulatory T cells. Transplantation 2008; 86: 865-874.
180. WU J, YI S, OUYANG L et al. In vitro expanded human CD4+CD25+ regulatory T cells are potent suppressors of T-cell-mediated xenogeneic responses. Transplantation 2008; 85: 1841-1848.
181. SUN L, YI S, O'CONNELL PJ. Foxp3 regulates human natural CD4+CD25+ regulatory T-cell-mediated suppression of xenogeneic response. Xenotransplantation 2010; 17: 121-130.
182. O'CONNELL PJ, YI S, CARRINGTON EM, LEW AM. Role of regulatory T cells in xenotransplantation. Curr Opin Organ Transplant 2010; 15: 224-229.
183. DONS EM, RAIMONDI G, COOPER DKC, THOMSON AW. Non-human primate regulatory T cells: current biology and implications for transplantation. Transplantation 2010; 90: 811-816.
184. WEBSTER NL, FORNI M, BACCI ML et al. Multi-transgenic pigs expressing three fluorescent proteins produced with high efficiency by sperm mediated gene transfer. Mol Reprod Dev 2005; 72: 68-76.
185. NOTTLE MB, VASSILIEV I, O'CONNELL PJ, D'APICE AJ, COWAN PJ. On the need for porcine embryonic stem cells to produce Gal KO pigs expressing multiple transgenes to advance xenotransplantation. Xenotransplantation 2010; 17: 411-412.
186. DENG W, YANG D, ZHAO B et al. Use of the 2A peptide for generation of multi- transgenic pigs through a single round od nuclear transfer. PLoS ONE 2011; 6: e19986 Doi: 10.1371/journal.pone.0019986.
187. FISICARO N, LONDRIGAN SL, BRADY JL et al. Versatile coexpression of graft- protective proteins using 2A-linked cassettes. Xenotransplantation 2011; 18: 121-130.
188. BIBIKOVA M, GOLIC M, GOLIC KG, CARROLL D. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 2002; 161: 1169-1175.
189. CARROLL D. Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther 2008; 15: 1463-1468.
190. KLUG A. The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem 2010; 79: 213-231.
191. URNOV FD, REBAR EJ, HOLMES MC, ZHANG HS, GREGORY PD. Genome editing with engineered zinc finger nucleases. Nature 2010; 11: 636-646.
192. WATANABE M, UMEYAMA K, MATSUNARI H et al. Knockout of exogenous EGFP gene in porcine somatic cells using zinc-finger nucleases. Biochem Biophys Res Commun 2010; 402: 14-18.
193. HAUSCHILD J, PETERSEN B, SANTIAGO Y et al. Efficient generation of a biallelic knockout in pigs using zinc-finger nucleases. Proc Natl Acad Sci U S A 2011; 108: 12013-12017.
194. HAUSCHILD J, PETERSEN B, SANTIAGO Y et al. Zinc-finger nuclease mediated knockout of the porcine alpha1, 3-galactosyltransferase gene. Xenotransplantation 2011; 18: 270 (Abstract #124).
195. TESSON L, USAL C, MÉNORET S et al. Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol 2011; 29: 695-696.
196. IZMIRYAN A, BASMACIOGULLARI S, HENRY A et al. Efficient gene targeting mediated by a lentiviral vector-associated meganuclease. Nucleic Acids Res 2011; 39: 7610-7619.
197. GARRELS W, MÁTÉS L, HOLLER S et al. Germline transgenic pigs by sleeping beauty transposition in porcine zygotes and targeted integration in the pig genome. PLoS ONE 2011; 6: e23573.
198. KRANER S, MERKL C, SCHNIEKE A. Genes, BACs, and artificial chromosomes. Xenotransplantation 2011; 18: 56-72.
199. GALLI C, PEROTA A, BRUNETTI D, LAGUTINA I, LAZZARI G, LUCCHINI F. Genetic engineering including superseding microinjection: new ways to make GM pigs. Xenotransplantation 2010; 17: 397-410.
200. KOBAYASHI T, YAMAGUCHI T, HAMANAKA S et al. Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. Cell 2010; 142: 787-799.
201. PHELPS C, VAUGHT T, BALL S et al. Multi-transgenic pigs designed for xenoislet transplants. Xenotransplantation 2009; 16: 374 (Abstract # IXA-O-7.3).
202. AYARES D, VAUGHT T, BALL S et al. Islet-specific expression of TFPI, CD39, and CTLA4Ig in transgenic pigs designed for xenoislet transplantation. Xenotransplantation 2011; 18: 269 (Abstract #119).
203. BAEHR A, VAN BUERCK L, KUROME M et al. LEA29Y transgenic pigs for overcoming cellular rejection in xenotransplantation. Xenotransplantation 2011; 18: 271 (Abstract #128).
204. MARTIN C, PLAT M, NERRIÉRE-DAGUIN V et al. Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation. Transgenic Res 2005; 14: 373-384.
205. BADIN RA, PADOAN A, VADORI M et al. Long-term clinical recovery in parkinsonian monkey recipients of CTLA4-Ig transgenic porcine neural precursors. Transplantation 2010; 90(Suppl. 2): 47 (Abstract #LB-3288).
206. LÉVÊQUE X, COZZI E, NAVEILHAN P, NEVEU I. Intracerebral xenotransplantation: recent findings and perspectives for local immunosuppression. Curr Opin Organ Transplant 2011; 16: 190-194.
207. AYARES D, PHELPS C, VAUGHT T et al. Multi-transgenic pigs for vascularized pig organ xenografts. Xenotransplantation 2011; 18: 269 (Abstract #119).
208. COOPER DKC. A brief history of cross-species organ transplantation. Proc (Bayl Univ Med Cent) 2012; 25: 49-57.